Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Receivables: 2019-2025

Historic Change in Receivables for Seres Therapeutics (MCRB) over the last 5 years, with Sep 2025 value amounting to $351,000.

  • Seres Therapeutics' Change in Receivables rose 101.89% to $351,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.3 million, marking a year-over-year increase of 50.63%. This contributed to the annual value of -$8.7 million for FY2024, which is 200.00% down from last year.
  • Per Seres Therapeutics' latest filing, its Change in Receivables stood at $351,000 for Q3 2025, which was up 101.89% from -$18.6 million recorded in Q3 2024.
  • Seres Therapeutics' Change in Receivables' 5-year high stood at $11.2 million during Q2 2024, with a 5-year trough of -$18.6 million in Q3 2024.
  • Its 3-year average for Change in Receivables is $50,143, with a median of $351,000 in 2025.
  • As far as peak fluctuations go, Seres Therapeutics' Change in Receivables crashed by 2,962.03% in 2021, and later skyrocketed by 101.89% in 2025.
  • Seres Therapeutics' Change in Receivables (Quarterly) stood at -$1.2 million in 2021, then reached -$8.2 million in 2023, then crashed by 300.05% to -$18.6 million in 2024, then surged by 101.89% to $351,000 in 2025.
  • Its Change in Receivables was $351,000 in Q3 2025, compared to -$18.6 million in Q3 2024 and $11.2 million in Q2 2024.